Verification of a Blood-Based Targeted Proteomics Signature for Malignant Pleural Mesothelioma.

Ferdinando CercielloMeena ChoiSara L Sinicropi-YaoKatie LomeoJoseph M AmannEmanuela Felley-BoscoRolf A StahelBruce W S RobinsonJenette CreaneyHarvey I PassOlga VitekDavid P Carbone

Published in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2020)

The proteomic signature represents an additional diagnostic approach for informing clinical decisions for patients at risk for MPM.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
mass spectrometry
peritoneal dialysis
cancer therapy
patient reported outcomes